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Summary
Background Trials of intermittent preventive treatment (IPTp) of malaria in pregnant women that compared 
dihydroartemisinin-piperaquine with the standard of care, sulfadoxine-pyrimethamine, showed dihydroartemisinin-
piperaquine was superior at preventing malaria infection, but not at improving birthweight. We aimed to assess 
whether sulfadoxine-pyrimethamine shows greater non-malarial benefits for birth outcomes than does 
dihydroartemisinin-piperaquine, and whether dihydroartemisinin-piperaquine shows greater antimalarial benefits 
for birth outcomes than does sulfadoxine-pyrimethamine.
Methods We defined treatment as random assignment to sulfadoxine-pyrimethamine or dihydroartemisinin-
piperaquine before pooling individual participant-level data from 1617 HIV-uninfected pregnant women in Kenya 
(one trial; n=806) and Uganda (two trials; n=811). We quantified the relative effect of treatment on birthweight 
(primary outcome) attributed to preventing placental malaria infection (mediator). We estimated antimalarial 
(indirect) and non-malarial (direct) effects of IPTp on birth outcomes using causal mediation analyses, accounting for 
confounders. We used two-stage individual participant data meta-analyses to calculate pooled-effect sizes.
Findings Overall, birthweight was higher among neonates of women randomly assigned to sulfadoxine-pyrimethamine 
compared with women assigned to dihydroartemisinin-piperaquine (mean difference 69 g, 95% CI 26 to 112), despite 
placental malaria infection being lower in the dihydroartemisinin-piperaquine group (relative risk [RR] 0·64, 95% CI 
0·39 to 1·04). Mediation analyses showed sulfadoxine-pyrimethamine conferred a greater non-malarial effect than 
did dihydroartemisinin-piperaquine (mean difference 87 g, 95% CI 43 to 131), whereas dihydroartemisinin-
piperaquine conferred a slightly larger antimalarial effect than did sulfadoxine-pyrimethamine (8 g, –9 to 26), 
although more frequent dosing increased the antimalarial effect (31 g, 3 to 60).
Interpretation IPTp with sulfadoxine-pyrimethamine appears to have potent non-malarial effects on birthweight. 
Further research is needed to evaluate monthly dihydroartemisinin-piperaquine with sulfadoxine-pyrimethamine (or 
another compound with non-malarial effects) to achieve greater protection against malarial and non-malarial causes 
of low birthweight.
Funding Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bill & Melinda Gates 
Foundation, and Worldwide Antimalarial Resistance Network.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
In sub-Saharan Africa, malaria infection during 
pregnancy is a major cause of low birthweight. For 
pregnant women, red blood cells infected with 
Plasmodium falciparum sequester in the placenta, causing 
inflammatory cellular responses that lead to increased 
risk of preterm delivery (<37 gestational weeks) and 
intrauterine growth restriction, which are both causes 
of low birthweight (<2500 g).1–3 To prevent adverse 
consequences of malaria infection, WHO recommends 
the provision of intermittent preventive treatment (IPTp) 
with sulfadoxine-pyrimethamine to all pregnant women 
living in areas of moderate-to-high malaria transmission, 
administered at scheduled antenatal visits from the 
second trimester to delivery.4
Parasite resistance to sulfadoxine-pyrimethamine in 
eastern and southern Africa has led researchers to evaluate 
alternative drug regimens for IPTp. Dihydroartemisinin-
piperaquine remains the most promising candidate, given 
its long-acting prophylactic effect and highly efficacious 
antimalarial activity. To date, three trials5–7 in areas of 
high sulfadoxine-pyrimethamine resistance have shown 
that dihydroartemisinin-piper aquine is well-tolerated and 
more effective in preventing malaria infection than is 
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sulfadoxine-piperaquine. However, this effect did not 
translate into better birth outcomes.5–7 A plausible 
explanation for these results is that these studies lacked 
sufficient statistical power to detect differences in birth 
outcomes, as most of them were powered to detect 
differences in malaria outcomes, which were more 
prevalent. An alternative explanation is that sulfadoxine-
pyrimethamine, via the broad-spectrum antimicrobial 
activity of sulfadoxine, improves birth outcomes through 
mechanisms that are independent of its antimalarial 
activity (ie, via non-malarial mechanisms), and in these 
studies, the non-malarial effect has offset the greater 
antimalarial effect of dihydroartemisinin-piperaquine on 
birth outcomes. Studies support this alternative hypothesis, 
suggesting IPTp with sulfadoxine-pyrimethamine remains 
protective against low birthweight risk in areas with low 
malaria transmission8 or high parasite resistance to 
sulfadoxine-pyrimethamine.9–11
To test this alternative hypothesis, we aimed to use data 
from three randomised trials in Kenya and Uganda to 
assess whether sulfadoxine-pyrimethamine shows greater 
non-malarial benefits for birth outcomes than does 
dihydroartemisinin-piper aquine, and whether dihydroarte-
misinin-piperaquine shows great er antimalarial benefits 
for birth outcomes than does sulfadoxine-pyrimethamine. 
We used mediation analyses12,13 to estimate the non-
malarial and antimalarial effects of these two treatments. 
Mediation analysis is an epidemiological method that uses 
statistical modelling to examine quantitatively the extent to 
which certain intermediate variables mediate the overall 
effect of a treatment on an outcome. Mediation analysis is 
done by prespecifying a mediator and estimating the effect 
that a treatment has on an outcome either indirectly (via 
the mediator) or directly (via the non-mediated pathway). 
In this study, the term indirect effect is defined as the effect 
of IPTp on birthweight that is attributed to preventing 
placental malaria (ie, antimalarial effect). The term direct 
effect is defined as the effect of IPTp on birthweight that is 
not attributed to preventing placental malaria (ie, non-
malarial effect). Here, we present analyses of the relative 
overall, indirect, and direct effects of these two IPTp 
regimens on birth outcomes.
Methods
Study population
We collected individual participant-level data from three 
trials in Siaya County, Kenya (Kenya-STOPMiP),5 Tororo 
District, Uganda (Uganda-BC1),6 and Busia District, 
Research in context
Evidence before the study
We searched ClinicalTrials.gov and PubMed for original articles 
using the search terms “intermittent preventive treatment” 
AND “sulfadoxine-pyrimethamine” AND “malaria in 
pregnancy” OR “non-malarial effect” OR “bacterial vaginosis” 
OR “reproductive tract infections” OR “sexually transmitted 
infections”. No language or time restrictions were used in this 
search. We identified two observational studies, done in 
malarious regions of Zambia and Burkina Faso, and one 
editorial that addressed the potential non-malarial effect of 
sulfadoxine-pyrimethamine. Both observational studies found 
intermittent preventive treatment with sulfadoxine-
pyrimethamine in pregnant women (IPTp) had a dose-
dependent effect on birth outcomes, with one study reporting 
that IPTp with sulfadoxine-pyrimethamine was associated with 
reduced odds of sexually transmitted and reproductive tract 
infections, and overall adverse birth outcomes. The editorial, 
which cited a study done in a low malaria prevalence (<1%) 
setting of Zambia, reported that IPTp with sulfadoxine-
pyrimethamine conferred a protective effect on birth 
outcomes. However, none of these studies differentiated 
between the non-malarial and antimalarial effects of IPTp with 
sulfadoxine-pyrimethamine on adverse birth outcomes.
Added value of this study
To our knowledge, this is the first study to use mediation 
analysis on individual-participant data from randomised 
controlled trials of IPTp to deconstruct the non-malarial and 
antimalarial effects of sulfadoxine-pyrimethamine relative to 
dihydroartemisinin-piperaquine. Dihydroartemisinin-
piperaquine is one of the most promising candidates to replace 
sulfadoxine-pyrimethamine in IPTp regimens. Our findings 
show that IPTp with sulfadoxine-pyrimethamine confers a 
greater non-malarial effect on birthweight than does IPTp with 
dihydroartemisinin-piperaquine, but IPTp with 
dihydroartemisinin-piperaquine has moderately greater 
antimalarial effects on birthweight than does IPTp with 
sulfadoxine-pyrimethamine if given at monthly intervals.
Implications of all the available evidence
In areas with high parasite resistance to sulfadoxine-
pyrimethamine, IPTp with sulfadoxine-pyrimethamine could be 
more beneficial in improving birthweight through preventing 
the non-malarial causes of adverse pregnancy outcomes 
compared with IPTp with dihydroartemisinin-piperaquine. 
However, IPTp with dihydroartemisinin-piperaquine, when 
given monthly, has moderately greater antimalarial effects on 
birthweight than does IPTp with sulfadoxine-pyrimethamine. 
The combination of dihydroartemisinin-piperaquine plus a 
partner compound that confers protection against the non-
malarial causes of lower birthweight (eg, sulfadoxine-
pyrimethamine) could increase the public health effect of IPTp 
more than dihydroartemisinin-piperaquine or sulfadoxine-
pyrimethamine alone. However, further IPTp trials are needed 
to validate whether the combination of dihydroartemisinin-
piperaquine and sulfadoxine-pyrimethamine (or any 
combination that targets both the malarial and non-malarial 
causes of lower birthweight) would be safe and efficacious.
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Uganda (Uganda-BC3).7 In Siaya County, around 96% of 
parasites carry the quintuple antifolate mutation (pfdhfr 51I, 
59R, and 108N and pfdhps 437G and 540E) and 5·8% have 
the sextuple mutation (pfdhps A581G).9 In Tororo, Uganda, 
around 78% of parasites carry the quintuple mutation, 
whereas none have the sextuple mutation.14 No data were 
available on pfdhf/pfdhps mutations in Busia, although 
Tororo and Busia are adjacent districts.
Trial eligibility was restricted to HIV-uninfected 
pregnant women who were resident in the study region 
or health facility catchment area with no history of 
receiving IPTp during their current pregnancy.
In the Kenya-STOPMiP trial,5 women between 16 
and 32 gestational weeks of pregnancy were enrolled 
and randomly assigned to receive IPTp with 
dihydroartemisinin-piperaquine, IPTp with sulfadoxine-
pyrimethamine, or intermittent screening and treatment 
(ISTp) with dihydroartemisinin-piperaquine. Women 
assigned to IPTp groups received IPTp at enrolment and 
then at each subsequent antenatal visit at intervals of 
4–6 weeks.
In the Ugandan studies,6,7 women between 12 and 
20 gestational weeks of pregnancy were enrolled. In 
Uganda-BC1,6 women were randomly assigned to receive 
either IPTp with sulfadoxine-pyrimethamine every 
8 weeks, IPTp with dihydroartemisinin-piperaquine every 
8 weeks, or IPTp with dihydroartemisinin-piperaquine 
every 4 weeks. In Uganda-BC3,7 women were randomised 
to either IPTp with sulfadoxine-pyrimethamine or IPTp 
with dihydroartemisinin-piperaquine every 4 weeks. 
Women assigned to IPTp every 8 weeks began IPTp at 
20 gestational weeks of pregnancy, whereas women 
assigned to IPTp every 4 weeks began IPTp at 16 or 
20 gestational weeks of pregnancy, depending on their 
gestational age at enrolment.
For all studies, each dose of sulfadoxine-pyrimethamine 
was three tablets of 500 mg sulfadoxine and 25 mg of 
pyrimethamine given as a single dose. In Kenya-STOPMiP,5 
dosing of dihydroartemisinin-piperaquine was based on 
bodyweight at enrolment (two, three, or four tablets of 
40 mg dihydroartemisinin and 320 mg piperaquine per day 
for bodyweights of 24·0–35·9 kg, 36·0–74·9 kg; or 
≥75·0 kg, respectively) and given once a day for 3 days. In 
the Ugandan studies,6,7 each dose of dihydroartemisinin-
piperaquine was three tablets of 40 mg dihydroartemisinin 
and 320 mg piperaquine given once a day for 3 days. Single-
dose sulfadoxine-pyrimethamine and the first dose of 
dihydroartemisinin-piperaquine were administered under 
direct observation at the clinic, and the second and third 
doses of dihydroartemisinin-piperaquine were self-
administered at home. The Ugandan trials were placebo-
controlled such that all participants received a three-dose 
course. Participants in Kenya were visited at home 2 days 
after enrolment to verify drug adherence, and every fifth 
participant was visited at home on subsequent visits. For 
the Ugandan studies, standardised assessments were done 
to determine adherence.
Our mediation analysis included women who had 
singleton livebirths, received at least one IPTp dose, and 
a known status of either past or active placental malaria 
infection. Placental malarial infection was determined by 
including women who either had a histopathological 
assessment of placental malaria using placenta tissue or 
women who tested positive for placental malaria by 
either microscopy, loop-mediated isothermal amplifi-
cation, or PCR methods using placental blood. Women 
were excluded if they were assigned to the Kenya-
STOPMiP ISTp group, assigned to the Uganda-BC1 IPTp 
with dihydroartemisinin-piperaquine every 4 weeks 
group, or had an unknown status of either past or active 
placental malaria (ie, missing placental histopathology 
results and negative for placental malaria by microscopy 
and molecular methods).
Ethics approvals were granted by the Kenya Medical 
Research Institute, Makerere University School of 
Biomedical Sciences, the Uganda National Council for 
Science and Technology, the US Centers for Disease 
Control and Prevention, and the University of California, 
San Francisco.
Measurement of treatment, mediator, and confounders 
We defined treatment as random assignment to IPTp 
with either sulfadoxine-pyrimethamine or dihydroartemi-
sinin-piperaquine. The mediator in our analysis was 
defined as the presence of previous or active placental 
malaria infection. A woman was determined to have a 
previous or active placental malaria infection if she had 
pigment or parasites in her placenta determined by 
histopathology of the placental tissue15 or if she tested 
positive for parasites by microscopy or molecular 
methods in her placental blood. Peripherally-detected 
malaria infection was considered a potential mediator 
(appendix 2 p 1) but we found that, in our sample of 
women, parasitaemia without the presence of placental 
malaria was not associated with lower birthweight, 
whereas women with placental malaria, regardless of 
whether they had peripherally-detected malaria, were 
more likely to have a baby with a lower birthweight.
Confounding variables were identified a priori based on 
causal assumptions represented in a directed acyclic graph 
(appendix 2 p 2). Because of treatment randomi sation, 
confounders were limited to those that affected mediator–
outcome associations. These included gestational age at 
enrolment, maternal age, maternal parasitaemia at enrol-
ment, gravidity, education, and household wealth. Gravid-
ity was dichotomised as primigravidae (first pregnancy) 
or multigravidae (one or more previous pregnancies). 
Household wealth was reported as tertiles and calculated 
using principal components analysis of common 
household items.
Outcomes
The primary outcome was a continuous measure of 
birthweight at delivery measured in g. Secondary outcomes 
See Online for appendix 2
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were low birthweight (<2500 g) and preterm delivery 
(<37 gestational weeks). Further details on measurement 
of these outcomes are reported in the trials.5–7
Statistical analysis
We used causal mediation analysis16–18 to deconstruct the 
crude differences in birth outcomes between IPTp 
Figure 1: Flowchart of participants from the Kenya-STOPMiP, Uganda-BC1, and Uganda-BC3 IPTp trials who were included in our primary analysis
IPTp=intermittent preventive treatment.
2641 women enrolled
1559 in Kenya-STOPMiP
300 in Uganda-BC1
782 in Uganda-BC3
1017 assigned to IPTp with sulfadoxine-pyrimethamine
520 in Kenya-STOPMiP; doses at every antenatal care visit
106 in Uganda-BC1; 8-week dose
391 in Uganda-BC3; 4-week dose
1008 assigned to IPTp with dihydroartemisinin-piperaquine
523 in Kenya-STOPMiP; doses at every antenatal care visit
94 in Uganda-BC1; 8-week dose
391 in Uganda-BC3; 4-week dose
899 followed up through to delivery
466 in Kenya-STOPMiP
99 in Uganda-BC1
334 in Uganda-BC3
894 followed up through to delivery
466 in Kenya-STOPMiP
89 in Uganda-BC1
339 in Uganda-BC3
805 included in analyses
402 from Kenya-STOPMiP
94 from Uganda-BC1
309 from Uganda-BC3
812 included in analyses
404 in Kenya-STOPMiP
84 in Uganda-BC1
324 in Uganda-BC3
2025 randomised
616 excluded
516 excluded in the ISTp with 
dihydroartemisinin-piperaquine group 
from the Kenya-STOPMiP study
100 excluded in the 4-week 
dihydroartemisinin-piperaquine group 
from the Uganda-BC1 study
118 excluded
54 excluded from Kenya-STOPMiP
53 withdrew before delivery
1 spontaneous abortion
7 excluded from Uganda-BC1
4 withdrew before delivery
3 spontaneous abortions
57 excluded from Uganda-BC3
53 withdrew before delivery
4 spontaneous abortions
114 excluded
57 excluded from Kenya-STOPMiP
54 withdrew before delivery
3 spontaneous abortion
5 excluded from Uganda-BC1
5 withdrew before delivery
52 excluded from Uganda-BC3
42 withdrew before delivery
10 spontaneous abortions
94 excluded
64 excluded from Kenya-STOPMiP
12 non-singleton pregnancies
1 delivered before study drugs 
given
37 placental malaria not assessed
14 stillbirth deliveries
5 excluded from Uganda-BC1
2 non-singleton pregnancies
3 placental malaria not assessed
25 excluded from Uganda-BC3 
women
10 non-singleton pregnancies
12 placental malaria not assessed
3 stillbirth deliveries
82 excluded
62 excluded from Kenya-STOPMiP
19 non-singleton pregnancies
40 placental malaria not assessed
3 stillbirth deliveries
5 excluded from Uganda-BC1
4 non-singleton pregnancies
1 placental malaria not assessed
15 excluded from Uganda-BC3
3 non-singleton pregnancies
10 placental malaria not
2 stillbirth deliveries
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regimens (ie, overall treatment effect) into the difference 
in birth outcomes between IPTp regimens that is 
mediated by preventing placental malaria (ie, indirect or 
antimalarial effect) and the difference in birth outcomes 
between IPTp regimens that is not mediated by 
preventing placental malaria infection (ie, direct or non-
malarial effect; appendix 2 pp 2–3).
We estimated crude differences in birth outcomes 
between IPTp regimens using linear or log-binomial 
regression models with random assignment as the sole 
predictor. For mediation analyses, we used the 
mediation R package19 to estimate indirect and direct 
effects (appendix 2 p 3). We ran separate models to 
specify the dependence of placental malaria and birth 
outcomes based on treatment and prespecified 
confounders (as described in the assumed causal graph; 
appendix 2 p 2). Predicted values from these models 
were used in a Monte-Carlo framework to calculate 
indirect and direct effect estimates and corresponding 
95% CIs, which we report as mean differences for 
birthweight and relative risks for low birthweight and 
preterm delivery.
For all models, treatment–gravidity and treatment–
mediator interaction terms were tested wherever possible 
and incorporated if the p values (pinteraction) of these terms 
were less than 0·10. We modelled continuous predictors as 
three-knot restricted cubic splines if the p value of the 
F test for the joint-effect of the non-linear components was 
less than 0·05. CIs around mediation effect estimates were 
generated for each study with a quasi-Bayesian approach 
using 1000 simulations. Effect modification by gravidity of 
indirect and direct effect estimates was tested using the 
test.modmed() function19 with corresponding p values 
reported as pdifference. For the mediator and primary outcome 
(placental malaria and birthweight, respectively), we report 
effect estimates separately for each study and by gravidity, 
regardless of whether there was evidence of a statistical 
interaction. Analyses of secondary outcomes (low birth-
weight and preterm delivery) were not reported separately 
by gravidity as they were relatively uncommon.
Kenya-STOPMiP5 Uganda-BC16 Uganda-BC37
Sulfadoxine-
pyrimethamine 
(n=402)
Dihydroartemisinin-
piperaquine (n=404)
Sulfadoxine-
pyrimethamine 
(n=94)
Dihydroartemisinin-
piperaquine (n=84)
Sulfadoxine-
pyrimethamine 
(n=309)
Dihydroartemisinin-
piperaquine (n=324)
At enrolment
Age at enrolment (years) 23·7 (5·9) 23·3 (5·4) 21·5 (3·7) 22·2 (4·4) 24·0 (6·0) 24·0 (5·7)
Weight (kg) 61·6 (9·0) 61·7 (9·3) 55·5 (6·9) 55·6 (6·9) 56·0 (7·8) 55·8 (7·8)
Gestational age (weeks) 22·7 (19·7–26·3) 22·9 (19·9–26·1) 14·9 (13·4–16·9) 14·9 (14·0–16·6) 15·7 (13·4–17·9) 15·1 (13·4–17·1)
Wealth index tertiles
Lowest 133 (33%) 124 (31%) 36 (38%) 28 (33%) 103 (33%) 112 (35%)
Middle 139 (35%) 133 (33%) 27 (29%) 32 (38%) 102 (33%) 110 (34%)
Highest 128 (32%) 145 (36%) 31 (33%) 24 (29%) 104 (34%) 102 (31%)
Level of education
None or primary 241 (60%) 233 (58%) 75 (80%) 67 (80%) 238 (77%) 244 (75%)
Secondary and beyond 159 (40%) 167 (42%) 19 (20%) 17 (20%) 71 (23%) 80 (25%)
Gravidity
Primigravidae (first pregnancy) 144 (36%) 125 (31%) 34 (36%) 28 (33%) 81 (26%) 71 (22%)
Multigravidae (second or later pregnancy) 258 (64%) 279 (69%) 60 (64%) 56 (67%) 228 (74%) 253 (78%)
Slept under a net during previous night 288 (72%) 292 (72%) 81 (86%) 77 (92%) 104 (34%) 108 (33%)
Maternal parasitaemia* 126 (33%) 120 (31%) 52 (55%) 50 (60%) 254 (82%) 257 (79%)
Maternal haemoglobin (g/dL) 10·6 (1·5) 10·6 (1·5) 11·8 (1·5) 11·9 (1·1) 11·4 (1·4) 11·4 (1·2)
Following enrolment
Number of intermittent preventive treatment doses received
1 20 (5%) 11 (3%) 0 0 0 0
2 158 (39%) 179 (44%) 6 (6%) 5 (6%) 1 (1%) 0
3 110 (27%) 114 (28%) 88 (94%) 79 (94%) 2 (1%) 1 (1%)
4 85 (21%) 68 (17%) 0 0 6 (2%) 7 (2%)
5 25 (6%) 29 (7%) 0 0 80 (26%) 79 (24%)
6 4 (1%) 3 (1%) 0 0 155 (50%) 152 (47%)
7 0 0 0 0 65 (22%) 85 (26%)
Data are mean (SD), median (IQR), or n (%). Values many not sum to totals because of missing data. *Malaria parasitaemia assessed by loop-mediated isothermal amplification in the Uganda-BC1 study and by 
quantitative polymerase chain reaction in the Kenya-STOPMiP and Uganda-BC3 studies.
Table: Characteristics of study populations by study and randomised treatment group
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We generated pooled-effect estimates using two-stage 
individual participant data meta-analyses. Individual 
participant data were used to derive effect estimates for 
each study and combined using a DerSimonian-Laird 
random-effects model from the meta R package.20 
Between-study heterogeneity was measured using the 
I² statistic. Analyses were done using Stata version 14.0 
and R version 3.5.0.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
Figure 2: Crude differences in placental malaria risk (A) and birthweight (B) between IPTp groups by study and gravidity subgroup
ANC=antenatal care. IPTp=intermittent preventive treatment. RR=relative risk.
Favours dihydroartemisinin-piperaquine Favours sulfadoxine-pyrimethamine
Study siteA Crude placental malariaIPTp dosing
Sulfadoxine-
pyrimethamine
Dihydroartemisinin-
piperaquine
Risk of placental malaria
All gravidae
Kenya-STOPMiP
Uganda-BC1
Uganda-BC3
Random-effects model
Heterogeneity: I2=92%; p<0·0001
Primigravidae
Kenya-STOPMiP
Uganda-BC1
Uganda-BC3
Random-effects model
Heterogeneity: I2=44%; p=0·17
Multigravidae
Kenya-STOPMiP
Uganda-BC1
Uganda-BC3
Random-effects model
Heterogeneity: I2=93%; p<0·0001
Siaya County
Tororo District
Busia District
Siaya County
Tororo District
Busia District
Siaya County
Tororo District
Busia District
Every ANC visit
Every 8 weeks
Every 4 weeks
Every ANC visit
Every 8 weeks
Every 4 weeks
Every ANC visit
Every 8 weeks
Every 4 weeks
149/402 (37·1%)
48/94 (51·1%)
200/309 (64·7%)
80/144 (55·6%)
25/34 (73·5%)
76/81 (93·8%)
69/258 (26·7%)
23/60 (38·3%)
124/228 (54·4%) 
136/404 (33·7%)
27/84 (32·1%)
95/324 (29·3%)
63/125 (50·4%) 
20/28 (71·4%) 
49/71 (69·0%)
 73/279 (26·2%)
7/56 (12·5%)
46/253 (18·2%)
0·91 (0·75 to 1·09)
0·63 (0·44 to 0·91)
0·45 (0·38 to 0·55)
0·64 (0·39 to 1·04)
0·91 (0·72 to 1·14)
0·97 (0·71 to 1·32)
0·74 (0·62 to 0·87)
0·84 (0·70 to 1·00)
0·98 (0·74 to 1·30)
0·32 (0·15 to 0·70)
0·33 (0·25 to 0·45)
0·49 (0·21 to 1·12)
0·31
0·011
<0·0001
0·40
0·85
0·0001
0·88
0·0015
<0·0001
35·2%
29·5%
35·2%
100·0%
33·7%
31·1%
35·2%
100·0%
39·6%
21·0%
39·4%
100·0%
RR (95% CI) p value Weight
n/N (%)
0·2 0·5 1·0 2·0 5·0
Study siteB Crude birthweightIPTp dosing
Sulfadoxine-
pyrimethamine
Dihydroartemisinin-
piperaquine
Birthweight
All gravidae
Kenya-STOPMiP
Uganda-BC1
Uganda-BC3
Random-effects model
Heterogeneity: I2=0%; p=0·58
Primigravidae
Kenya-STOPMiP
Uganda-BC1
Uganda-BC3
Random-effects model
Heterogeneity: I2=25%; p=0·26
Multigravidae
Kenya-STOPMiP
Uganda-BC1
Uganda-BC3
Random-effects model
Heterogeneity: I2=0%; p=0·86
Siaya County
Tororo District
Busia District
Siaya County
Tororo District
Busia District
Siaya County
Tororo District
Busia District
Every ANC visit
Every 8 weeks
Every 4 weeks
Every ANC visit
Every 8 weeks
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3102 (461)
3150 (477)
2773 (469)
2892 (438)
3348 (451)
3087 (407)
3176 (446)
3190 (439)
2963 (452)
3038 (401)
3044 (466)
2826 (529)
2910 (348)
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3031 (396)
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87 (24 to 150)
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writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Our primary analysis included 1617 women—806 from 
Kenya-STOPMiP,5 178 from Uganda-BC1,6 and 633 from 
Uganda-BC37 (figure 1). 1024 (39%) of 2641 women 
enrolled across the three studies were excluded for the 
following reasons: 516 women randomly assigned to non-
IPTp group; 100 women enrolled in the Uganda-BC1 
monthly dihydroartemisinin-piperaquine group and did 
not have a monthly sulfadoxine-pyrimethamine group as a 
study-specific comparator; 211 women withdrew from the 
study before delivery; 21 women had a spontaneous 
abortion, 22 women had a stillbirth, and 50 women had a 
non-singleton pregnancy; 103 women did not have 
placental malaria assessed; and one woman did not receive 
any study drug. The proportions of women excluded from 
each category were similar between IPTp groups (p>0·05).
Baseline characteristics and the number of IPTp doses 
given were similar between IPTp groups (table). In 
Kenya-STOPMiP,5 all women participating in random 
home visits adhered to taking their second and third 
IPTp doses. Self-reported adherence to second and third 
IPTp doses was 99% in Uganda-BC16 and 98% in 
Uganda-BC3.7
In the pooled analysis, dihydroartemisinin-piperaquine 
was associated with a lower risk of placental malaria 
infection compared with sulfadoxine-pyrimethamine, 
but this finding did not reach statistical significance 
(relative risk [RR] 0·64, 95% CI 0·39–1·04). There was 
substantial heterogeneity between studies (I²=92%; 
p<0·0001) and effects differed between primigravidae 
and multigravidae in the Ugandan studies (figure 2). In 
Kenya-STOPMiP, dihydroartemisinin-piperaquine was 
not associated with a substantially lower risk of placental 
malaria (RR 0·91, 95% CI 0·75–1·09) and effects were 
similar between primigravidae and multigravidae 
(pinteraction=0·68). In the Ugandan studies, dihydroartemi-
sinin-piperaquine was associated with a significantly 
lower risk of placental malaria compared with 
sulfadoxine-pyrimethamine (RR 0·63, 95% CI 0·44–0·91 
in Uganda-BC1 and 0·45, 0·38–0·55 in Uganda-BC3) 
and effects were larger in multigravidae compared with 
primigravidae (figure 2; pinteraction=0·0095 for Uganda-BC1 
and pinteraction=<0·0001).
Although dihydroartemisinin-piperaquine was associ-
ated with a lower risk of placental malaria compared with 
sulfadoxine-pyrimethamine, neonates born to mothers 
randomly assigned to dihydroartemisinin-piperaquine had 
lower birthweight (mean difference in pooled analysis 
69 g, 95% CI 26–112; figure 2). Effect estimates were 
similar between studies (I²=0%; p=0·58). In Kenya-
STOPMiP, the mean difference was 87 g (95% CI 24–150) 
and effects were similar between primigravidae and 
multigravidae (pinteraction=0·82). In Ugandan studies, 
sulfadoxine-pyrimethamine was not associated with a 
Figure 3: Crude differences in low birthweight (A) and preterm delivery (B) between IPTp groups by study
IPTp=intermittent preventive treatment. ANC=antenatal care. RR=relative risk.
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significantly higher birthweight compared with dihydro-
artemisinin-piperaquine and there was insufficient 
evidence that effects differed by gravidity (pinteraction Uganda-
BC1=0·43; pinteraction Uganda-BC3=0·13). However, risks of 
low birthweight (ie, <2500 g) and preterm delivery did not 
significantly differ between IPTp regimens, overall or for 
any of the three individual studies (figure 3).
In mediation analyses, dihydroartemisinin-piperaquine 
did not show a significantly larger antimalarial effect on 
birthweight than did sulfadoxine-pyrimethamine in the 
pooled analysis (mean difference 8 g, 95% CI –9 to 26), 
although effect estimates varied between studies (I²=51%; 
p=0·13; figure 4). The effect size was larger and 
statistically significant in the Uganda-BC3 study, in 
which IPTp was given monthly (mean difference 31 g, 
95% CI 3 to 60). In the other studies, in which most 
women received three or less IPTp doses (table 1), the 
mean difference was 2 g, with CIs that included the null. 
We found no evidence that antimalarial effects differed 
between primigravidae and multigravidae in any of the 
three studies (pdifference>0·63).
Antimalarial effects on low birthweight showed similar 
patterns to birthweight. In pooled analyses, the 
antimalarial effects on low birthweight were similar 
Figure 4: Effect of IPTp regimens on birthweight (A), low birthweight (B), and preterm delivery (C), mediated by placental malaria
Birthweight mediation effect estimates are presented by gravidity subgroup. ANC=antenatal care. IPTp=intermittent preventive treatment. RR=relative risk.
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between IPTp groups (RR 0·98, 95% CI 0·88–1·08), 
although effect estimates were heterogeneous between 
studies (I²=57%; p=0·10; figure 4). Compared with 
the Kenya-STOPMiP and Uganda-BC1 studies, which 
showed null differences between IPTp regimens 
(RR 1·02, 95% CI 0·96–1·10 and 1·03, 0·84–1·26, 
respectively), the Uganda-BC3 study (in which IPTp was 
dosed monthly) showed that dihydroartemisinin-
piperaquine conferred a greater and statistically sig-
nificant antimalarial effect on low birthweight than did 
sulfadoxine-pyrimethamine (0·88, 0·78–0·99). Anti-
malarial effects on preterm delivery risk were similar 
between IPTp regimens (1·08, 95% CI 0·95–1·22) in the 
pooled analysis and across the three studies (I²=0%; 
p=0·93; figure 4).
In the pooled analysis, sulfadoxine-pyrimethamine 
conferred a greater non-malarial effect on birthweight 
than did dihydroartemisinin-piperaquine (mean 
difference 87 g, 95% CI 43 to 131; figure 5). Effects were 
similar across studies (I²=0%; p=0·51) and we found no 
evidence that the non-malarial effects differed between 
primigravidae and multigravidae in the Kenya-STOPMiP 
and Uganda-BC1 study (pdifference>0·33). In the Uganda-
BC3 study, sulfadoxine-pyrimethamine conferred a 
greater non-malarial effect than did dihydroartemisinin-
piperaquine in multigravidae, but not in primigravidae 
Figure 5: Effect of IPTp regimens on birthweight (A), low birthweight (B), and preterm delivery (C), not mediated by placental malaria
Birthweight mediation effect estimates are presented by gravidity subgroup. ANC=antenatal care. IPTp=intermittent preventive treatment. RR=relative risk.
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(mean difference 133 g, 95% CI 51 to 216 vs –10 g, 
–143 to 123, respectively; pdifference=0·094).
The non-malarial effect on low birthweight had a 
similar relationship to the continuous measure of 
birthweight (figure 5). In the pooled analysis, sulfadoxine-
pyrimethamine conferred a 22% (or 100 × [1–1/1·28]) 
greater non-malarial effect on low birthweight risk 
compared with dihydroartemisinin-piperaquine (RR 1·28, 
95% CI 0·85–1·93), although CIs included the null. Low 
birthweight effect estimates were similar between studies 
(I²=0%; p=0·40).
In the pooled analysis, sulfadoxine-pyrimethamine 
was associated with a 13% (or 100 × [1–1/1·15]) greater 
non-malarial effect on preterm delivery risk than 
was dihydroartemi sinin-piperaquine (RR 1·15, 95% CI 
0·50–2·65), although CIs around all effect estimates 
included the null (figure 5). Effects varied between 
studies (I²=48%; p=0·15), particularly between Kenyan 
and Ugandan studies.
We did sensitivity analyses to test the robustness of our 
effect estimates. First, we restricted the definition of our 
mediator to active placental infections only, as past 
infections include those that might have been present 
before study enrolment. Dihydroartemisinin-piperaquine 
was associated with a lower risk of active infections 
compared with sulfadoxine-pyrimethamine (appendix 2 
p 4), and we found that mediation effect estimates on 
birthweight did not substantially differ from the primary 
analyses (appendix 2 p 5). Second, we tested the 
robustness of our effect estimates to unmeasured 
mediator-outcome confounding (appendix 2 p 6). We 
found that the strength of an unmeasured confounder 
would have to be implausibly large to explain away our 
observed non-malarial effect, but not our antimalarial 
effect estimate.
Discussion
By pooling data from three randomised controlled trials, 
we found evidence that IPTp influences birthweight 
through both antimalarial and non-malarial mech-
anisms. Crude analyses of data from these trials showed 
that, despite the substantially larger protective effect of 
dihydroartemisinin-piperaquine on placental malaria, 
birthweight was higher for neonates of women randomly 
assigned to sulfadoxine-pyrimethamine. We did medi-
ation analyses to investigate this seemingly paradoxical 
relationship. We found, via mechanisms mediated 
by malaria prevention, that monthly IPTp with 
dihydroartemisinin-piperaquine (as observed in the 
Uganda-BC3 study) was associated with a modest, but 
significant increase in birthweight (31 g) compared with 
sulfadoxine-pyrimethamine. By contrast, there was little 
difference in the antimalarial effect on birthweight 
between IPTp groups in studies with less frequent 
IPTp dosing (ie, Kenya-STOPMiP and Uganda-BC1). We 
found that, via mechanisms not mediated by malaria, 
sulfadoxine-pyrimethamine was associated with a 
significant increase in birthweight (87 g) compared with 
dihydroartemisinin-piperaquine, and this effect was 
similar across studies. Antimalarial effects on preterm 
delivery risk did not follow birthweight or low birthweight 
trends, suggesting the mechanism by which IPTp affects 
birthweight might be via promotion of intrauterine fetal 
growth, rather than timing of delivery. We observed some 
evidence in Uganda that non-malarial effects were 
greater in multigravidae, which might reflect a greater 
attributable fraction of non-malarial causes of low 
birthweight compared with primigravidae, for whom 
malaria might be a more predominant cause of low 
birthweight.
Although we do not know the exact non-malarial 
mechanisms by which sulfadoxine-pyrimethamine is 
improving birthweight, it is likely that the antibiotic 
properties of sulfadoxine are, at least partly, responsible 
for these observed effects.8,21,22 Sulfadoxine belongs to a 
group of agents (sulfonamides) that have been previously 
used to treat Trichomonas vaginalis,23 Gardnerella vaginalis 
(a bacterium associated with bacterial vaginosis),24 
Neisseria gonorrhoeae,25 and Chlamydia trachomatis.26 
These infections are prevalent among pregnant women 
in east Africa (range 3·7–50·8%).27 Although sulfadoxine-
pyrimethamine is unlikely to cure these infections, 
antenatal dosing has been shown to reduce adverse 
pregnancy outcomes among women who had these 
non-malarial infections at antenatal booking.28 There 
are probably other mechanisms at play, which warrant 
future study, including those affected by the broad-
spectrum antibacterial activity of sulfadoxine.29 For 
example, sulfadoxine might alter the maternal intestinal 
or vaginal microbiome to stimulate fetal growth21,22 or 
modulate maternal immunity, similar to effects described 
for the related antifolate combination trimethoprim-
sulfa methoxazole.11 Although identifying the specific 
mechanisms underlying the non-malarial effect of 
sulfadoxine-pyrimethamine were not within the scope of 
this study, our findings show that IPTp with sulfadoxine-
pyrimethamine could be used to prevent the non-malarial 
causes of lower birthweight, which might be just as 
important as, if not more so, than preventing placental 
malaria infection.
In the Uganda-BC3 study, 457 (73%) of 633 women 
received at least six IPTp doses, whereas in the Kenya-
STOPMiP and Uganda-BC1 study, 592 (73%) of 806 and 
178 (100%) of 178 women received three or less IPTp 
doses, respectively. More frequent dosing could explain 
why the antimalarial effect of dihydroartemisinin-
piperaquine was larger in the Uganda-BC3 study than 
the other studies. Our findings support the results of the 
original Uganda-BC1 study,6 which found that dihydro-
artemi sinin-piperaquine administered every 4 weeks was 
associated with lower malaria and adverse birth outcome 
risk than when administered every 8 weeks. Thus, to take 
advantage of the full antimalarial benefits of IPTp with 
dihydroartemisinin-piperaquine, partic ularly in areas of 
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high sulfadoxine-pyrimethamine resistance or high 
malaria burden, doses should be given at monthly 
intervals and as early in the second trimester as possible.
This study has limitations. First, mediation effect 
estimates might have been subject to unmeasured 
confounding, although our sensitivity analyses suggest 
non-malarial effects were fairly robust. Second, placental 
malaria (mediator) could have been measured with error, 
which would have probably, on average, have biased the 
antimalarial and non-malarial effect toward the null. 
However, a sensitivity analysis using a more specific 
definition of the mediator (active placental malaria 
infections) showed similar results. Third, our meta-
analysis effect estimates were derived from only three 
studies and should be interpreted with caution. Finally, 
our study might have had low statistical power to detect 
true differences between gravidity subgroups and further 
studies are needed to support our findings.
In conclusion, mediation analyses enabled us to quan-
tify the greater benefits of sulfadoxine-pyrimethamine 
against the non-malarial causes of lower birthweight 
compared with dihydroartemisinin-piperaquine, and the 
greater bene fits of monthly dihydroartemisinin-piperaquine 
against placental malaria as a cause of lower birth-
weight compared with sulfadoxine-pyrimethamine. These 
findings have two important policy implications. First, this 
study suggests that IPTp with sulfadoxine-pyrimethamine 
might be beneficial in areas of low malaria transmission, 
where IPTp is not currently recommended, as long as 
the prevalence of these non-malarial causes are high. 
Second, the study suggests that in areas of high 
sulfadoxine-pyrimethamine resistance or high malaria 
burden, rather than replacing sulfadoxine-pyrimethamine 
with dihydroartemisinin-piperaquine, a combination of 
these two regimens for monthly IPTp administration 
might be more efficacious in improving birthweight. 
Future IPTp trials need to validate the efficacy and safety 
of this combination. Provided IPTp with sulfadoxine-
pyrimethamine and dihydroartemisinin-piper aquine is 
safe and efficacious, this regimen or other combinations 
that target both malarial and non-malarial causes of lower 
birthweight (eg, dihydroartemisinin-piper aquine plus 
azithromycin30 or dihydroartemisinin-piper aquine plus 
metronidazole31) might have a greater public health impact 
than giving either therapy alone.
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